Drugs / 211-astatine MX35 F(ab')2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04461457 | Feb 2005 → Mar 2011 | ovarian cancer | Vastra Gotaland Region | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 211-astatine MX35 F(ab')2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04461457 ↗ |
| Known as | (211)At-MX35 F(ab')2 | “Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.” PMID 19525452 ↗ Jun 2009 |
| Modality | Monoclonal antibody | “Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2.” NCT04461457 ↗ |
| Route | Other | “receive one intra peritoneal infusion” NCT04461457 ↗ |